¼¼°è ¹«½ºÄ«¸°¼º ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü ½ÃÀå ¿¹Ãø(-2030³â) : À¯Çü, Á¦Ç°, À¯Åë ä³Î, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº° ºÐ¼®
Muscarinic Acetylcholine Receptor Market Forecasts to 2030 - Global Analysis By Type (M1, M4, M5 and Other Types), Product (Tropicamide, Nu-0467154, Anauex-273 and Other Products), Distribution Channel, Application, End User and By Geography
»óǰÄÚµå : 1401866
¸®¼­Ä¡»ç : Stratistics Market Research Consulting
¹ßÇàÀÏ : 2023³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200+ Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,150 £Ü 5,715,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,230,000
PDF (2-5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,350 £Ü 8,745,000
PDF & Excel (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,500 £Ü 10,329,000
PDF & Excel (Global Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 10ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Stratistics MRC¿¡ µû¸£¸é ¼¼°è ¹«½ºÄ«¸°¼º ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü ½ÃÀåÀº 2023³â 17¾ï 5,000¸¸ ´Þ·¯¿¡ À̸£°í, ¿¹Ãø ±â°£ µ¿¾È CAGR 6.9%·Î ¼ºÀåÇØ 2030³â¿¡´Â 27¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹«½ºÄ«¸°¼º ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü´Â ½Ã³À½º ÈÄ ´º·±À» ¾ïÁ¦ÇÒ ¼ö ÀÖ´Â ¼ö¿ëüÀÇ ÀÏÁ¾À¸·Î, ¿©·¯ ¸»ÃÊ ¹× ÁßÃß È°µ¿ÀÇ Á¶Àý¿¡ °ü¿©ÇÕ´Ï´Ù. ºÎ±³°¨½Å°æ°èÀÇ »ý¸®Àû °á°ú¸¦ Á¶ÀýÇÏ´Â ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¾ïÁ¦ ¹× ÈïºÐ ÀÛ¿ëÀ» ¸ðµÎ °¡Áö°í ÀÖÀ¸¸ç, ¹ÝÀÀÀ» Â÷´ÜÇϰųª ÀÚ±Ø ÇÒ ¼ö ÀÖÀ¸¸ç, Äݸ°¼º ´º·±À¸·Î ¾Æ¼¼Æ¿Äݸ° »ý¼º ´º·±¿¡ ÀúÀåµË´Ï´Ù.

ÀÇÇÐ ¿¬±¸¸¦ Áö¿øÇÏ´Â ¹Ì±¹ ºñ¿µ¸®´ÜüÀÎ ¹Ì±¹½ÉÀåÇùȸ¿¡ µû¸£¸é, ¹Ì±¹ ³» ¾ËÃ÷ÇÏÀ̸Ӻ´ ¹× °ü·Ã Ä¡¸Å ȯÀÚ ¼ö´Â 2060³â±îÁö 930¸¸ ¸íÀ¸·Î ´Ã¾î³¯ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½Å°æ ÁúȯÀÇ À¯º´·ü Áõ°¡

¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, Á¤½ÅºÐ¿­Áõ°ú °°Àº ½Å°æÁúȯÀº Àα¸ÀÇ °í·ÉÈ­¿Í ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È­·Î ÀÎÇØ ´õ¿í È®»êµÇ°í ÀÖ½À´Ï´Ù. ¹«½ºÄ«¸°¼º ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü´Â ÀÌ·¯ÇÑ Áúȯ¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, ÀǾàǰ °³¹ßÀÇ ¸Å·ÂÀûÀÎ ´ë»óÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ½Å°æ°è ÁúȯÀÇ ºÎ´ãÀ» ÇØ°áÇØ¾ß ÇÏ´Â Àý½ÇÇÑ Çʿ伺°ú Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÌ ºÐ¾ßÀÇ Á¦¾àȸ»ç¿Í ¿¬±¸Àڵ鿡°Ô Å« ÀáÀç·ÂÀ» °¡Á®´ÙÁÖ´Â µ¿½Ã¿¡ ȯÀڵ鿡°Ôµµ Èñ¸ÁÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

ºÎÀÛ¿ë ¹× ¾ÈÀü¼º ¹®Á¦

¹«½ºÄ«¸°¼º ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â ¾à¹°Àº ±¸°­°ÇÁ¶Áõ, ¾È±¸°ÇÁ¶Áõ, º¯ºñ, ¾îÁö·³Áõ, ÀÎÁöÀå¾Ö¿Í °°Àº ºÎÀÛ¿ëÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÎÀÛ¿ëÀº ȯÀÚÀÇ ¼øÀÀµµ¿Í »îÀÇ Áú¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖÀ¸¸ç, ƯÈ÷ ³ëÈ­¿Í °ü·ÃµÈ ¹®Á¦·Î ÀÎÇØ ÀÌ·¯ÇÑ Áõ»óÀ» ÀÌ¹Ì °æÇèÇϰí ÀÖÀ» ¼ö ÀÖ´Â °í·ÉÀÚ Áý´Ü¿¡¼­ ´õ¿í ±×·¯ÇÕ´Ï´Ù. Ä¡·á È¿°ú¿Í ºÎÀÛ¿ëÀÇ ±ÕÇüÀ» ¸ÂÃß´Â °ÍÀº ¾î·Æ°í, ȯÀÚÀÇ ¼øÀÀµµ¸¦ Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÉÇ÷°ü°è ¹× È£Èí±â °èÅë¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö Àֱ⠶§¹®¿¡ ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·Áµµ Á¦±âµË´Ï´Ù. µû¶ó¼­ ½ÃÀå È®´ë¿¡ °É¸²µ¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

Ç¥ÀûÄ¡·á

Ç¥Àû Ä¡·á´Â º¸´Ù Á¤È®ÇÑ Ä¡·á ¿É¼ÇÀ» Á¦°øÇϰí, ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸç, Ä¡·á °á°ú¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ȯÀÚ °³°³ÀÎÀÇ ¼ö¿ëü ÇÁ·ÎÆÄÀÏ¿¡ ¸ÂÃá ÁßÀ縦 ÅëÇØ °³ÀÎ ¸ÂÃãÇü ÀÇ·á°¡ Çö½ÇÈ­µÇ¾î ¾ËÃ÷ÇÏÀ̸Ӻ´, Á¤½ÅºÐ¿­Áõ, ÆÄŲ½¼º´ µîÀÇ Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å³ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾à¹° Àü´Þ ½Ã½ºÅÛ°ú Áø´Ü µµ±¸ÀÇ ¹ßÀüÀº ÀÌ·¯ÇÑ Ä¡·á È¿°ú¸¦ ÃÖÀûÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â Á¦¾àȸ»ç¿Í ¿¬±¸ÀÚµéÀÌ Çõ½ÅÀûÀ̰í ȯÀÚ Áß½ÉÀÇ ¼Ö·ç¼ÇÀ» °³¹ßÇÏ¿© ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ´Â À¯¸ÁÇÑ ±æÀ» Á¦½ÃÇÕ´Ï´Ù.

±ÔÁ¦»óÀÇ Àå¾Ö¹°

¹«½ºÄ«¸° ¼ö¿ëü¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â ¾à¹°À» °³¹ßÇϱâ À§Çؼ­´Â ´ë±Ô¸ð ÀÓ»ó½ÃÇè°ú ¾ÈÀü¼º Æò°¡ µî ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀ» ÁؼöÇØ¾ß ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿ä±¸»çÇ×Àº °³¹ß ±â°£ÀÇ ¿¬Àå, ºñ¿ë Áõ°¡, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ Ãë¼ÒÀÇ À§ÇèÀ» ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. Áö¿¬°ú °ÅÀýÀº ½ÃÀå ÁøÀÔÀ» ¹æÇØÇϰí Á¦¾à»çÀÇ ¹ß¸ñÀ» Àâ´Â´Ù. ÀÌ·¯ÇÑ Àå¾Ö¹°Àº Çõ½ÅÀ» ÀúÇØÇÏ°í ½Å°æ ¹× Á¤½Å Áúȯ¿¡ ´ëÇÑ »õ·Î¿î Ä¡·á¹ý Á¦°øÀ» Áö¿¬½ÃÄÑ ½ÃÀå ¼ºÀå°ú °æÀï¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

Äڷγª19ÀÇ À¯ÇàÀº ±ÙÀ° ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. °ø±Þ¸Á Áß´Ü, R&D ¾÷¹«ÀÇ Á¦ÇÑ, ÀÇ·á ÀÚ¿øÀÇ ÀçÆí µîÀ¸·Î ÀÎÇØ ÀÓ»ó½ÃÇè°ú ÀǾàǰ °³¹ßÀÌ Áö¿¬µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹«½ºÄ«¸° ¼ö¿ëü °ü·Ã ÀǾàǰ¿¡ ´ëÇÑ È¯ÀÚÀÇ Á¢±Ù¼ºÀº ¿ø°Ý ÀÇ·á¿¡ ´ëÇÑ °­Á¶¿Í ´ë¸é Áø·áÀÇ °¨¼Ò·Î ÀÎÇØ ¿µÇâÀ» ¹Þ¾Ò½À´Ï´Ù. ±×·¯³ª Àü¿°º´Àº ½Å°æÇÐ ¿¬±¸¿Í ±â¼ú Çõ½ÅÀÇ Á߿伺À» °­Á¶Çϰí ÀÇ·á ½Ã½ºÅÛÀÌ ¹Ì·¡ÀÇ µµÀü°ú ±âȸ¿¡ ÀûÀÀÇÔ¿¡ µû¶ó ÀÌ ½ÃÀå¿¡ ´ëÇÑ °ü½É°ú ÅõÀÚ°¡ Áõ°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È Æ®·ÎÇÇÄ«¹Ìµå ºÐ¾ß°¡ °¡Àå Å« ½ÃÀåÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Æ®·ÎÇÇÄ«¹Ìµå ºÐ¾ß°¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. Æ®·ÎÇÇÄ«¹Ìµå´Â Ç×Äݸ°Á¦ ¶Ç´Â ¹«½ºÄ®¸° ±æÇ×Á¦·Î ¾Ë·ÁÁø ¾à¹°±º¿¡ ¼ÓÇÏ´Â ÀǾàǰÀÔ´Ï´Ù. ¾È°ú ¿µ¿ª¿¡¼­´Â ÁÖ·Î »çÀÌŬ·ÎÇÁ·» ÀÛ¿ëÁ¦ ¹× »êµ¿Á¦·Î »ç¿ëµË´Ï´Ù. Æ®·ÎÇÇÄ«¹Ìµå´Â ȫä¿Í ¸ð¾çü±ÙÀÇ ¹«½ºÄ«¸°¼º ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü¸¦ ¾ïÁ¦ÇÏ¿© ¾È±¸ÀÇ ÃÊÁ¡ Á¶Àý ±ÙÀ°À» ¸¶ºñ½ÃÄÑ µ¿°øÀ» È®´ë½Ãŵ´Ï´Ù. Æ®·ÎÇÇÄ«¹ÌµåÀÇ ¾È°ú ¿µ¿ªÀ¸·ÎÀÇ Àû¿ëÀº Á¤½ÅÁúȯ°ú ½Å°æÁúȯÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ ÁúȯÀ» Ä¡·áÇϱâ À§ÇØ ÀÌ ¼ö¿ëü¸¦ Ç¥ÀûÀ¸·Î »ï´Â ¾à¹°°ú Ä¡·á¹ýÀ» Æ÷ÇÔÇÑ ´õ Å« ½ÃÀå°úÀÇ ¿¬°ü¼ºÀ» °­Á¶ÇÕ´Ï´Ù.

Á¤½ÅÁúȯ ºÐ¾ß´Â ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¤½ÅÁúȯ ºÐ¾ß´Â ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹«½ºÄ«¸°¼º ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü´Â ÁßÃ߽Űæ°è¿¡ Á¸ÀçÇÏ´Â ¼ö¿ëü ±×·ìÀ¸·Î ´Ù¾çÇÑ ³ú ±â´É Á¶Àý¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ ¼ö¿ëüÀÇ ±â´É Àå¾Ö´Â Á¤½ÅºÐ¿­Áõ, ¾ç±Ø¼º Àå¾Ö, ÁÖ¿ä¿ì¿ïÁõ µî ¿©·¯ Á¤½ÅÁúȯ¿¡ °ü¿©ÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº Á¤½Å ÁúȯÀ» ¾Î°í ÀÖ´Â »ç¶÷µé¿¡°Ô º¸´Ù È¿°úÀûÀ̰í Ç¥ÀûÈ­µÈ Ä¡·á¸¦ Á¦°øÇÒ ¼ö ÀÖ´Â Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖÀ¸¸ç, ÀÌ´Â ÀÇ·á ¹ßÀüÀ» À§ÇÑ À¯¸ÁÇÑ ¼ö´ÜÀÌ µÇ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ ºÐ¾ß¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª

¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á ÁöÃâ Áõ°¡¿Í ³ëÀÎ Àα¸ Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ½ÃÀå¿¡´Â ½Å°æ°è¿¡ ÇʼöÀûÀÎ ¼ººÐÀÎ ¹«½ºÄ«¸°¼º ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü¿Í °ü·ÃµÈ ÀǾàǰ, ¿¬±¸ µµ±¸ ¹× Áø´Ü µµ±¸°¡ Æ÷ÇԵ˴ϴÙ. ÀÌ ½ÃÀåÀº ½Å°æ ÁúȯÀÇ À¯Çà, ÀǾàǰ °³¹ßÀÇ ¹ßÀü, ½Å°æÇÐ ¿¬±¸ Áõ°¡ µîÀÇ ¿äÀο¡ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ªÀÇ ÁÖ¿ä Á¦¾à»ç, ¿¬±¸±â°ü ¹× »ý¸í°øÇÐ ±â¾÷µéÀº ÀÌ·¯ÇÑ ¼ö¿ëü °ü·Ã Á¦Ç°ÀÇ °³¹ß ¹× »ó¿ëÈ­¸¦ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. Çаè¿Í »ê¾÷°èÀÇ °øµ¿¿¬±¸°¡ ÀϹÝÀûÀ̸ç, Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ Á¢±Ù°ú Ç¥ÀûÄ¡·á´Â ÀÌ Áö¿ª¿¡¼­ °³ÀÎ ¸ÂÃãÇü ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö´Â °ÍÀ» ¹Ý¿µÇÏ´Â ÁÖ¿ä Æ®·»µåÀÔ´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª :

ºÏ¹Ì´Â Àß ±¸ÃàµÈ ÀÇ·á ÀÎÇÁ¶ó, ³ôÀº R&D ÅõÀÚ, ¸¹Àº ȯÀÚ ¼ö·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ¼öÀͼº ÀÖ´Â ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ±Ô¸ð´Â ÀÌ·¯ÇÑ ¼ö¿ëü °ü·Ã ÁúȯÀÇ À¯Çà, ÀǾàǰ °³¹ßÀÇ ¹ßÀü, ½Å°æÇÐ ¹× °ü·Ã ºÐ¾ßÀÇ ¿¬±¸¿Í °°Àº ¿äÀο¡ ÀÇÇØ ¿µÇâÀ» ¹Þ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾àȸ»çµéÀº ¾ËÃ÷ÇÏÀ̸Ӻ´°ú °°Àº ½Å°æ ÁúȯÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ Áúȯ¿¡ ´ëÇØ ¹«½ºÄ«¸°¼º ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â ¾à¹°À» °³¹ßÇϰí ÀÖ½À´Ï´Ù.

¹«·á ¸ÂÃãÇü ¼­ºñ½º

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½°ú °°Àº ¹«·á ¸ÂÃãÈ­ ¿É¼Ç Áß Çϳª¸¦ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

Á¦4Àå PorterÀÇ Five Forces ºÐ¼®

Á¦5Àå ¼¼°èÀÇ ¹«½ºÄ«¸°¼º ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü ½ÃÀå : À¯Çüº°

Á¦6Àå ¼¼°èÀÇ ¹«½ºÄ«¸°¼º ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü ½ÃÀå : Á¦Ç°º°

Á¦7Àå ¼¼°èÀÇ ¹«½ºÄ«¸°¼º ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü ½ÃÀå : À¯Åë ä³Îº°

Á¦8Àå ¼¼°èÀÇ ¹«½ºÄ«¸°¼º ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü ½ÃÀå : ¿ëµµº°

Á¦9Àå ¼¼°èÀÇ ¹«½ºÄ«¸°¼º ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ¼¼°èÀÇ ¹«½ºÄ«¸°¼º ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü ½ÃÀå : Áö¿ªº°

Á¦11Àå ÁÖ¿ä ¹ßÀü

Á¦12Àå ±â¾÷ °³¿ä

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

According to Stratistics MRC, the Global Muscarinic Acetylcholine Receptor Market is accounted for $1.75 billion in 2023 and is expected to reach $2.79 billion by 2030 growing at a CAGR of 6.9% during the forecast period. Muscarinic acetylcholine receptors are a class of receptors that can inhibit postsynaptic neurons and are involved in the regulation of several peripheral and central activities. They are responsible for regulating the parasympathetic nervous system's physiological consequences. It has both inhibitory and excitatory effects that can block or stimulate the response and is stored in the acetylcholine-producing neurons as cholinergic neurons.

According to the American Heart Association, a US-based nonprofit organization that supports medical research, the number of persons affected by Alzheimer's disease and associated dementias in the United States is expected to rise to 9.3 million by 2060.

Market Dynamics:

Driver:

Increasing prevalence of neurological disorders

Neurological conditions, such as Alzheimer's disease, Parkinson's disease, and schizophrenia, are becoming more widespread due to ageing populations and changing lifestyles. Muscarinic acetylcholine receptors play a crucial role in these disorders, making them attractive targets for drug development. Moreover, the market is growing as a result of a dire need to address the burden of neurological illnesses on healthcare systems and the growing need for innovative therapies. This presents both significant possibilities for pharmaceutical companies and researchers in the field, as well as potential hope for patients.

Restraint:

Side effects and safety concerns

Medications targeting muscarinic acetylcholine receptors can lead to adverse effects such as dry mouth, blurred vision, constipation, dizziness, and cognitive impairment. These side effects can impact patient compliance and quality of life, particularly in elderly populations that may already experience some of these symptoms due to age-related issues. Balancing therapeutic benefits with side effects is challenging, potentially limiting patient adherence. Safety concerns also arise due to the potential impact on cardiovascular and respiratory systems. Thus, they are limiting market expansion.

Opportunity:

Targeted therapies

Targeted therapies can offer more precise treatment options, minimising side effects and enhancing therapeutic outcomes. By tailoring interventions to the individual patient's receptor profile, personalised medicine becomes a reality, potentially revolutionising the treatment of conditions like Alzheimer's disease, schizophrenia, and Parkinson's disease. Furthermore, advancements in drug delivery systems and diagnostic tools can optimise the effectiveness of these therapies. This presents a promising avenue for pharmaceutical companies and researchers to develop innovative, patient-centric solutions and drive growth in the market.

Threat:

Regulatory hurdles

Developing drugs targeting muscarinic receptors requires adherence to rigorous regulatory requirements, including extensive clinical trials and safety assessments. These demands lead to extended timelines, increased costs, and the risk of regulatory setbacks. Delays or rejections can hinder market entry and deter pharmaceutical companies. These obstacles may impede innovation, potentially delaying the availability of new treatments for neurological and psychiatric disorders and impacting the market's growth and competitiveness.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the muscle acetylcholine receptor market. Clinical trial and medication development have been delayed as a result of supply chain interruptions, limitations imposed on research and development operations, and the reorganisation of healthcare resources. Additionally, patient access to muscarinic receptor-related medicines was impacted by the emphasis on telehealth and the decline in in-person healthcare visits. However, the pandemic also underscored the importance of neurological research and innovation, potentially driving increased interest and investment in this market as healthcare systems adapt to future challenges and opportunities.

The Tropicamide segment is expected to be the largest during the forecast period

The Tropicamide segment is estimated to hold the largest share. Tropicamide is a pharmaceutical medication that belongs to a class of drugs known as anticholinergics or muscarinic antagonists. In ophthalmology, it is mainly employed as a cycloplegic and mydriatic agent. Tropicamide works by paralysing the focusing muscle of the eye and dilatation of the pupil by inhibiting muscarinic acetylcholine receptors in the iris and ciliary muscle. The application of tropicamide in ophthalmology highlights its connection to the larger market, which includes medications and treatments that target these receptors to treat a range of illnesses, including psychological and neurological diseases.

The Psychiatric Disorders segment is expected to have the highest CAGR during the forecast period

The Psychiatric Disorders segment is anticipated to have lucrative growth during the forecast period. Muscarinic acetylcholine receptors are a group of receptors in the central nervous system that play a crucial role in regulating various brain functions. Dysfunction in these receptors is implicated in several psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder. This segment of the market focuses on innovative therapies that can offer more effective and targeted treatments for individuals suffering from psychiatric conditions, representing a promising avenue for medical advancements. Hence, this will propel segment demand.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to rising healthcare expenditures and a growing geriatric population. It encompasses pharmaceuticals, research tools, and diagnostics associated with muscarinic acetylcholine receptors, vital components in the nervous system. This market is influenced by factors such as the prevalence of neurological disorders, advancing drug development, and increasing research in neurology. Moreover, major pharmaceutical companies, research institutions, and biotechnology firms in the region engage in the development and commercialization of products related to these receptors. Collaborations between academia and industry are common, and precision medicine approaches and targeted therapies are key trends, reflecting a growing focus on personalised healthcare solutions in the region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to the presence of a well-established healthcare infrastructure, high research and development investments, and a large patient population. The market size is influenced by factors such as the prevalence of conditions related to these receptors, advancements in drug development, and research in neurology and related fields. Furthermore, pharmaceutical companies develop drugs targeting muscarinic acetylcholine receptors for various medical conditions, including neurological disorders like Alzheimer's disease.

Key players in the market:

Some of the key players in the Muscarinic Acetylcholine Receptor Market include AstraZeneca, Anavex Life Sciences Corp., Sosei Heptares, Karuna Therapeutics, Sumitomo Dainippon Pharma Co., Ltd., NeuroHealing Pharmaceuticals Inc., Heptares Therapeutics Ltd., Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Johnson & Johnson, Boehringer Ingelheim International Gmbh, Eli Lilly and Company, Takeda Pharmaceutical Company Ltd, Merck & Co., Inc, AbbVie Inc., Elsevier B.V., Eurofins DiscoverX Corporation and Novus Biologicals.

Key Developments:

In November 2023, AstraZeneca announces multi-year partnership with NHL and NHLPA Hockey Fights Cancer initiative. Through this multi-year partnership, AstraZeneca, the NHLPA, and the NHL will leverage the Hockey Fights Cancer platform to encourage fans to win at their own G.A.M.E: Gauge risk factors, Arrange a screening, make a donation, Educate loved ones.

In July 2023, AstraZeneca India strengthens partnership with SASTRA University. The collaboration between AstraZeneca and SASTRA University aims to strengthen industry-academia ties and equip students with expertise in various aspects of clinical research.

In June 2023, AstraZeneca has entered into an exciting collaboration, exclusive option and license agreement with Quell Therapeutics to develop multiple engineered T-regulator (Treg) cell therapies that have the potential to be curative in Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD) indications.

Types Covered:

Products Covered:

Distribution Channels Covered:

Applications Covered:

End Users Covered:

Regions Covered:

What our report offers:

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Table of Contents

1 Executive Summary

2 Preface

3 Market Trend Analysis

4 Porters Five Force Analysis

5 Global Muscarinic Acetylcholine Receptor Market, By Type

6 Global Muscarinic Acetylcholine Receptor Market, By Product

7 Global Muscarinic Acetylcholine Receptor Market, By Distribution Channel

8 Global Muscarinic Acetylcholine Receptor Market, By Application

9 Global Muscarinic Acetylcholine Receptor Market, By End User

10 Global Muscarinic Acetylcholine Receptor Market, By Geography

11 Key Developments

12 Company Profiling

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â